Statins and the Reduction of Sudden Cardiac Death: Antiarrhythmic or Anti-Ischemic Effect?

Abhimanyu Beri; Tahmeed Contractor; Atul Khasnis; Ranjan Thakur

Disclosures

Am J Cardiovasc Drugs. 2010;10(3):155-164. 

In This Article

5. Conclusion

Sudden cardiac death remains an important public health concern and occurs predominantly in low-risk populations. The effects of statins on sudden cardiac death reduction have only been analyzed in high-risk groups, mostly through observational studies or post hoc analysis of RCTs. Although statins have been shown to reduce sudden cardiac death and VT/VF in subjects with underlying coronary artery disease, similar benefits have not been consistently demonstrated in patients with non-ischemic cardiomyopathy.

The benefits of statins in reducing VT/VF and sudden cardiac death in low-risk populations remain unclear. Many studies do not report the use of specific statins thereby precluding the conclusion of whether or not this is a 'class-effect'. The exact mechanism underlying the reduction in VT/VF and sudden cardiac death by statins is also under debate. Based on existing studies, an anti-ischemic effect seems to be more likely than a direct antiarrhythmic effect. Because ICDs help ascertain arrhythmic events definitively, further trials involving high-risk subjects with ICDs placed for non-ischemic etiologies will be best able to evaluate primary antiarrhythmic effects of statins.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....